Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Artiva Biotherapeutics, Inc. ARTV NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
65/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$20.50
+125.3%

Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology company in the Healthcare sector, currently trading at $9.10. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ARTV = $21 (+125.3% upside).

Valuation: ARTV trades at a trailing Price-to-Earnings (P/E) of -2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.

Net income is $84M (loss), growing at -34%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $11M against $110M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 8.61 (strong liquidity). Debt-to-assets is 8.4%. Total assets: $131M.

Analyst outlook: 4 / 4 analysts rate ARTV as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 83/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

$20.50
▲ 125.27% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Artiva Biotherapeutics, Inc., the average price target is $20.50, with a high forecast of $23.00, and a low forecast of $18.00.
Highest Price Target
$23.00
Average Price Target
$20.50
Lowest Price Target
$18.00

ARTV SharesGrow Score Overview

77/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 83/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ARTV

✓
VALUE Pass
83/100
ARTV trades at a trailing Price-to-Earnings (P/E) of -2 (S&P 500 average ~25). Forward PEG 0.11 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.21. Analyst consensus target is $21, implying +130.8% from the current price $9. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ARTV: +126.7%/yr revenue is, -34%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ARTV: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 8.61 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
ARTV: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate ARTV as buy (100%). Analyst consensus target is $21 (+130.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.47-7.754
Volume875.38K
Avg Volume (30D)175.57K
Market Cap$224.92M
Beta (1Y)2.19
Share Statistics
EPS (TTM)-3.43
Shares Outstanding$24.44M
IPO Date2024-07-19
Employees96
CEOFred Aslan
Financial Highlights & Ratios
Gross Profit$-2.6M
EBITDA$-88.01M
Net Income$-83.87M
Operating Income$-90.61M
Total Cash$108.01M
Total Debt$10.94M
Net Debt$-15.76M
Total Assets$130.94M
Price / Earnings (P/E)-2.7
Analyst Forecast
1Y Price Target$20.50
Target High$23.00
Target Low$18.00
Upside+125.3%
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS04317A1079

Price Chart

Track all markets on TradingView
ARTV
Artiva Biotherapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.47 52WK RANGE 7.75

People Also View

ZNTL
ZNTL
Zentalis Pharmaceuticals, Inc.
$5.36
+3.08%
 STTK
STTK
Shattuck Labs, Inc.
$7.17
+5.75%
 STRO
STRO
Sutro Biopharma, Inc.
$29.77
+3.44%
 CNTB
CNTB
Connect Biopharma Holdings Limited
$2.93
-3.93%
 DTIL
DTIL
Precision BioSciences, Inc.
$7.66
+5.95%
 ADVM
ADVM
Adverum Biotechnologies, Inc.
$4.36
+0.00%
 ALXO
ALXO
ALX Oncology Holdings Inc.
$1.68
+4.02%
 IFRX
IFRX
InflaRx N.V.
$1.21
+6.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message